Skip to main content

Novo-Nordisk Value Stock - Dividend - Research Selection

Novo-Nordisk A/S

ISIN: DK0060534915, WKN: A1XA8R

Market price date: 28.05.2021
Market price: 481,00 DKK

Novo-Nordisk A/S Fundamental data and company key figures of the share

Annual reports in DKK
Key figures 26-05-2021
Cash flow
Net operating cash flow 51.951.000.000
Capital Expenditures -
Free cash flow 29.870.000.128
Balance sheet
Total Equity 63.325.000.000
Liabilities & Shareholders equity 144.922.000.000
Income statement
Net income
Eps (diluted) 18,008
Diluted shares outstanding 2.340.000.000
Net sales/revenue 126.946.000.000

Fundamental ratios calculated on: 28-05-2021

Key figures 28-05-2021
Cash flow
P/C 21,67
P/FC 37,68
Balance sheet
Income statement
Div. Yield1,89%

Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.

Market Capitalization159.427.182.592,00 USD
Raw Data SourceIFRS in Millionen DKK
Stock Split2014-01-10,5.0000/1.0000; 2014-01-09,5.0000/1.0000; 2007-12-18,2.0000/1.0000; 2007-12-17,2.0000/1.0000; 2001-04-12,5.0000/2.0000; 2001-04-11,5.0000/2.0000; 1994-04-19,4.0000/1.0000; 1994-04-18,4.0000/1.0000

Description of the company

Novo Nordisk A/S is a Denmark-based company engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company reports two business segments: Diabetes care and Biopharmaceuticals. The Diabetes care division offers a range of diabetes products, including insulin pens and needles, such as FlexPen, NovoPen and FlexTouch, among others, and diabetes medicine, such as insulin- and non-insulin treatment, among others. The Biopharmaceuticals division provides products within the areas of haemophilia, growth hormone therapy, hormone replacement therapy, inflammation therapy and other therapy areas. As of December 31, 2012, the Company marketed its products in five reported geographical regions, namely North America, Europe, Region China, Japan and Korea, as well as International Operations. The Company wholly owns over 70 subsidiaries, such as Novo Nordisk Pharma GmbH, Novo Nordisk Canada Inc., Novo Nordisk Region Japan & Korea A/S, among others.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources::,,